Business Context and Reporting Period
This Form 8-K was filed by Ekso Bionics Holdings, Inc. (trading symbol: EKSO) on October 22, 2019. The report details a material definitive agreement entered into on the same date by Ekso Bionics, Inc. ("Ekso US"), a wholly-owned subsidiary of the Company. The filing addresses the execution of a Technology License Agreement with Exoskeleton Intelligent Robotics Co. Limited, a joint venture formed to develop and serve the exoskeleton market in China and other Asian markets.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the terms of a new contractual agreement rather than periodic financial performance.
Material Changes and Agreement Terms
The primary material change is the execution of the Technology License Agreement, which grants the Joint Venture specific rights to Ekso US's technology. Key terms include:
- Licensed Territory: China, Hong Kong, Singapore, Malaysia, and other mutually agreed countries, explicitly excluding Japan, India, and Australia.
- Licensed Products: EksoGT, EksoVest, and EksoZeroG Arm units (collectively "Designated Products") and their improvements.
- Scope of License: Nontransferable, non-sublicensable, irrevocable, and exclusive rights to manufacture, assemble, use, and sell Designated Products within the territory, as well as provide marketing, training, and maintenance.
- Financial Consideration: Following a specified royalty-free period, Ekso US will receive mid-single digit percentages of the net sales revenue of Designated Products sold by the Joint Venture.
- Support Services: Ekso US will provide marketing, maintenance, training, and technical support, with the Joint Venture reimbursing reasonable costs and expenses.
- Duration: Effective until terminated for cause by Ekso US or upon the earlier expiration/termination of the underlying Joint Venture Agreement.
Outlook, Risks, and Contingencies
The agreement is designed to create a global exoskeleton manufacturing center and expand market presence in Asia. The filing notes that the summary of terms is qualified by the actual License Agreement, which will be filed as an exhibit to the Company's Annual Report on Form 10-K for the fiscal year ending December 31, 2019. No specific risks or contingencies beyond the standard termination clauses were detailed in this text.
Investor Verification Checklist
- Verify the specific duration of the "royalty-free period" mentioned in the agreement.
- Confirm the exact "mid-single digit" royalty percentage once the full agreement is filed in the 2019 Form 10-K.
- Review the full text of the Equity Joint Venture Contract and its April 2019 amendment to understand the governance structure of the Joint Venture.
- Monitor future filings for updates on the Joint Venture's manufacturing capabilities and sales performance in the designated territory.